New Study Associates Masimo SpHb, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion
55.43 hours 25.34 hours (48 hours median)
33.48 hours 12.25 hours (24 hours median)
0.001
179.02 mL 163.06 mL (145 mL)
102.69 mL 73.87 mL (105 mL)
0.033
71.96 mL 94.95 mL (25 mL)
28.15 mL 64.35 mL (0 mL)
0.043
462.59 mL 158.91 mL (500 mL)
0.048
270,821 74,474
1.47 mmol/L 0.64 mmol/L (1.25 mmol/L)
1.18 mmol/L 0.63 mmol/L (0.9 mmol/L)
0.044
They found that the length of stay in the ICU was statistically significantly higher in the control group than the SpHb group. Postoperative drainage, red blood cell transfusion, and fresh frozen plasma transfusion in the ICU were also statistically significantly higher in the control group than the SpHb group. Lactate levels were higher in the SpHb group at the start of the operation, but higher in the control group at the end.
Masimo
New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion
Thursday, December 10, 2020 2:34PM IST (9:04AM GMT)
Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at
Euroanaesthesia 2020 in which Dr. Saraçoğlu and colleagues at Marmara University in Istanbul, Turkey investigated the efficacy of Masimo noninvasive and continuous hemoglobin monitoring, SpHb
®, as part of the transfusion management of pediatric patients undergoing major surgery.
1 The researchers found that use of SpHb was associated with decreased rate of postoperative transfusion, reduced length of ICU stay, and other improved outcomes.